56172-36-2

Upstream product

• 50551-56-9 ethyl 5-methoxybenzofuran-2-carboxylate 
• 10242-08-7 5-methoxybenzofuran-2-carboxylic acid 
• 672-13-9 2-hydroxy-5-methoxybenzaldehyde 
• 782503-76-8 (Z)-4-(2,5-dimethoxybenzylidene)-2-methyloxazol-5(4H)-one 
• 93-02-7 2,5-dimethoxybenzaldehyde 
• 782503-80-4 (Z)-3-(2,5-Dimethoxy-phenyl)-2-hydroxy-acrylic acid 
• 1751-24-2 5-methoxy-benzofuran-2-carboxylic acid methyl ester 

Downstream Products

• 1646-28-2 5-hydroxy-benzofuran-2-carboxylic acid methyl ester 
• 99370-68-0 5-hydroxy-2-benzofuran-carboxylic acid ethyl ester 
• 1152424-93-5 N-(1-benzylpiperidin-4-yl)-5-hydroxybenzofurancarboxamide 
• 1093631-45-8 5-[4-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)phenyl]-1-benzofuran-2-carboxylic acid 
• 1093631-70-9 methyl 5-(4-hydroxyphenyl)-1-benzofuran-2-carboxylate 
• 155587-71-6 6-Amino-5-hydroxybenzofuran-2-carbonsaeure-methylester 

Relevant academic research and scientific papers

BITTER TASTE MODULATORS

The present invention includes antagonists of human type 2 taste receptors (hT2Rs) having structural Formula (I). The present invention also provides compositions containing these antagonists, the use of these antagonists for modulating taste perception, particularly bitter taste, and the method of preparing these antagonists (I).

CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS FOR METABOLIC DISORDERS

Disclosed are carboxamide, sulfonamide and amine compounds, as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure in which R1, R2, R4, E, T, n and x are as described h

FARNESOID X RECEPTOR AGONISTS

The present invention relates to famesoid X receptors (FXR, NR1 H4) FXR is a member of the nuclear receptor class of ligand-activated transcription factors More particularly, the present invention relates to compounds useful as agonists for FXR, pharmaceu

Heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitors

The present invention provides methods for the use of compounds as depicted by structure I, pharmaceutical compositions containing the same, and methods for the prophylaxis, management and treatment of metabolic diseases and diseases modulated by MCD inhi

COMPOUNDS AND METHODS OF USE

Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Antioxidant properties of 3-hydroxycoumarin derivatives

A series of hydroxylated 3-hydroxycoumarins was synthesised and evaluated for their antioxidant properties. The compounds substituted on the C-7 position were almost as antioxidant as quercetin or vitamin C. The antioxidant properties were related by an EPR study to their abilities to give stable semiquinonic or polyhydroxylated radicals. A series of hydroxylated 3-hydroxycoumarins was synthesised by the reaction of 3-aryl-2-hydroxypropenoic derivatives with boron tribromide. They were evaluated for their ability to scavenge the 2,2-diphenyl-1-picrylhydrazyl radical, the superoxide anion radical, the hydroxyl radical and the peroxynitrite anion and to inhibit copper-induced human LDL peroxidation. The physicochemical results were in accordance to establish the compounds hydroxylated on C-6 and C-7 positions as the most active of the series with antioxidant potencies comparable to those of quercetin and vitamin C. These compounds form o- and p-quinonoid derivatives upon radical scavenging and may serve as new lead compounds for pharmacological investigations.

Secondary amines as antidiabetic and antiobesity agents

The present invention relates to compounds of the formula STR1 having utility as hypoglycemic and antiobesity agents, methods for their use and pharmaceutical compositions containing them. The compounds of the present invention also possess utility for in

β3 -Adrenoceptor agonists and antagonists for the treatment of intestinal motility disorders, depression, prostate disease and dyslipidemia

This invention relates to methods for treating intestinal motility disorders, intestinal ulcerations, including inflammatory bowel disease, ulcerative colitis, Crohn''s disease and proctitis, and gastrointestinal ulcerations, depression, prostate disease

Synthesis and characterization of the furo and thieno analogues of the triester of PQQ

We report here the synthesis and properties of the furo and thieno analogues of 4,5-dihydro-4,5-dioxo-1H-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid (=PQQ), i.e. the furo- and thieno[2,3-f]quinoline-4,5-quinone (FQQ and TQQ, resp.) derivatives B and C, obtained as triesters. The triester of PQQ derivative A is much more stable than the triesters of B or C, and only the triester of A shows strong activity in nonenzymatic catalytic oxidations.